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Purpose: To assess the efficacy and safety of aripiprazole once-monthly 400 mg (AOM 400), 
an extended-release injectable suspension of aripiprazole, in obese and nonobese patients.
Patients and methods: This post hoc analysis of a 38-week randomized, double-blind, 
active-controlled, noninferiority study (NCT00706654) compared the clinical profile of AOM 
400 in obese (body mass index [BMI] 30 kg/m2) and nonobese (BMI 30 kg/m2) patients 
with schizophrenia for 3 years. Patients were randomized 2:2:1 to AOM 400, oral aripiprazole 
10–30 mg/d, or aripiprazole once-monthly 50 mg (AOM 50 mg) (subtherapeutic dose). Within 
obese and nonobese patient subgroups, treatment-group differences in Kaplan–Meier estimated 
relapse rates at week 26 (z-test) and in observed rates of impending relapse through week 38 
(chi-square test) were analyzed. Treatment-emergent adverse events (TEAEs) (10% in any 
treatment group) were summarized.
Results: At baseline of the randomized phase, obesity rates were similar among patients ran-
domized to AOM 400 (n=95/265, 36%), oral aripiprazole (n=95/266, 36%), and AOM 50 mg 
(n=43/131, 33%). In both obese and nonobese patients, relapse rates through week 38 for patients 
randomized to AOM 400 (obese, 7.4%; nonobese, 8.8%) were similar to those in patients on oral 
aripiprazole (obese, 8.4%; nonobese, 7.6%), whereas relapse rates were significantly lower with 
AOM 400 versus AOM 50 mg (obese, 27.9% [P=0.0012]; nonobese, 19.3% [P=0.0153]). The 
most common TEAEs with AOM 400 in obese and nonobese patients were insomnia (12.6% 
and 11.2%), headache (12.6% and 8.2%), injection site pain (11.6% and 5.3%), akathisia (10.5% 
and 10.6%), upper respiratory tract infection (10.5% and 4.7%), weight increase (10.5% and 
8.2%), and weight decrease (6.3% and 11.8%). Within the AOM 400 group, 7.6% of patients 
who were nonobese at baseline became obese, and 17.9% of obese patients became nonobese 
during randomized treatment.
Conclusion: The clinical profile of AOM 400 was similar in obese and nonobese patients.
Keywords: antipsychotic, long-acting injectable, schizophrenia, obesity, aripiprazole once-
monthly
Introduction
Schizophrenia is a chronic psychiatric disorder in which long-term antipsychotic 
treatment is recommended to reduce the risk of relapse.1,2 Many second-generation 
antipsychotics are associated with metabolic side effects such as weight gain.1,3–7 
Patients with schizophrenia often have comorbid medical conditions that may require 
continuous monitoring in addition to being observed for potential medication side 
effects.1,6,8,9 In a national survey of International Classification of Diseases, Ninth 
Edition discharge codes for patients hospitalized for schizophrenia, 63% of patients 
who had schizophrenia as their primary diagnosis had 1 comorbid condition.10 
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Metabolic risk factors, such as obesity, are also prevalent 
among patients with schizophrenia. A national, voluntary, 
cardiometabolic screening program of 10,000 patients 
in US public mental health clinics found that 53% of 
patients with schizophrenia were obese (body mass index 
[BMI] 30.0 kg/m2).11
Aripiprazole is an atypical antipsychotic with partial 
agonist activity at dopamine D
2
 receptors12 and a potentially 
less burdensome metabolic profile compared with other 
atypical antipsychotics.4,13,14 A once-monthly, long-acting 
injectable (LAI) formulation, aripiprazole once-monthly 
400 mg (AOM 400), is approved for the treatment of 
schizophrenia,15–17 making it the first dopamine D
2
 receptor 
partial agonist available in a long-acting formulation. Given 
the prevalence of obesity in patients with schizophrenia, it 
is important to consider the need for dose adjustments or 
special consideration in obese patients. Other LAI antipsy-
chotics, such as paliperidone palmitate, may require dose 
increases for overweight or obese patients with schizophre-
nia.18 This brief communication reports results from a post 
hoc analysis that evaluated the efficacy and tolerability 
of AOM 400 in obese and nonobese patients with schizo-
phrenia to provide guidance on whether dose adjustments 
may be needed.
Materials and methods
Patients and study design
Data are from a 38-week double-blind, multicenter, interna-
tional, active-controlled study that examined the clinical pro-
file of AOM 400 as maintenance treatment in patients with 
schizophrenia. The study was conducted from September 
2008 through August 2012 and recruited patients from 
Austria, Belgium, Chile, Croatia, Estonia, France, Hungary, 
Italy, Poland, South Africa, South Korea, Thailand, and the 
United States. Study design and patient inclusion/exclu-
sion criteria were previously described in detail.13 Briefly, 
adult patients aged 18–60 years with a diagnosis of schizo-
phrenia based on the Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision criteria for 
3 years and a history of symptom exacerbation when not 
receiving antipsychotic treatment were eligible for study 
inclusion. The study had three treatment phases, including 
an oral conversion phase (phase 1, cross-titration to oral arip-
iprazole and discontinuation of other antipsychotic) and an 
oral aripiprazole stabilization phase (phase 2). Patients who 
met the stability criteria with oral aripiprazole for 8 consecu-
tive weeks entered the double-blind, active-controlled phase 
(phase 3, up to 38 weeks) in which patients were randomized 
2:2:1 to AOM 400; oral aripiprazole (10–30 mg/d); or aripip-
razole once-monthly 50 mg (AOM 50 mg), a subtherapeutic 
dose included for assay sensitivity. Using a double-dummy 
design, patients in all treatment groups (including oral 
aripiprazole) received an injection into the gluteal muscle. 
Per protocol, patients whose BMI was 28 kg/m2 received 
injections with a 21-gauge, 1.5-inch needle, and patients 
whose BMI was 28 kg/m2 received injections with a 
21-gauge, 2-inch needle.16 Patients were able to reduce their 
AOM dose to 300 mg (or 25 mg in the AOM 50 mg group) 
for tolerability reasons and then subsequently increase their 
dose to 400 mg (or 50 mg in the AOM 50 mg group) on one 
occasion, if considered appropriate.13
assessments and statistical analyses
The primary endpoint – the noninferiority of AOM 400 to 
oral aripiprazole based on the Kaplan–Meier estimate of 
impending relapse rate at week 26 – was met, and results 
were previously described in detail.13 The current report is 
based on an exploratory post hoc analysis that was conducted 
in the subpopulations of obese (BMI 30 kg/m2) and non-
obese (BMI 30 kg/m2) patients, as determined at baseline 
of the double-blind phase. Estimated impending relapse 
rates at week 26 and the observed rate of impending relapse 
at week 38 were assessed. Impending relapse was defined 
as meeting 1 of the following criteria: (1) Clinical Global 
Impression-Improvement scale score of 5 (minimally 
worse) and either an increase on any of four individual Posi-
tive and Negative Syndrome Scale (PANSS) items (concep-
tual disorganization, hallucinatory behavior, suspiciousness, 
or unusual thought content) to a score 4 with an absolute 
increase of 2 on that specific item since randomization, 
or an increase to 4 on one of those PANSS items and an 
absolute increase of 4 on the combined score of those items; 
(2) hospitalization due to worsening of psychotic symptoms; 
(3) Clinical Global Impression-Severity of Suicidality score 
of four (severely suicidal) or five (attempted suicide) on part 1 
and/or six (much worse) or seven (very much worse) on part 2; 
or (4) violent behavior resulting in clinically relevant self-
injury, injury to another person, or property damage.13
Estimated impending relapse rate at week 26 was cal-
culated using Kaplan–Meier estimates, calculated as one – 
proportion of patients free of impending relapse events, 
using the intent-to-treat population, which included all 
patients randomized to double-blind treatment. Standard 
errors were calculated using Greenwood’s formula. Within 
obese and nonobese subgroups, treatment-group differences 
in estimated relapse rates at week 26 and in observed rates 
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of impending relapse through week 38 were analyzed using 
z-tests and chi-square tests, respectively.
To assess tolerability, the most common (10% incidence 
in any treatment group) treatment-emergent adverse events 
(TEAEs) were summarized within treatment groups in 
obese and nonobese patients; no formal statistical analyses 
were conducted. Within treatment groups (AOM 400, AOM 
50 mg, and oral aripiprazole 10–30 mg) the number and per-
centage of patients who went from obese to nonobese, and 
from nonobese to obese, from baseline of the double-blind 
phase to the end of the study were calculated. Mean change 
from baseline to study end on total scores of extrapyramidal 
symptom scales (EPS), including the Simpson–Angus Scale19 
total score, Barnes Akathisia Rating Scale20 global score, and 
Abnormal Involuntary Movement Scale21 rating score, were 
assessed among treatment groups for obese and nonobese 
patients. Metabolic parameters (ie, fasting total, LDL, and 
HDL cholesterol, fasting triglycerides, and fasting glucose) 
were monitored, and descriptive statistics, including mean 
change from baseline to study end, were calculated for obese 
and nonobese subgroups. For mean weight change from base-
line to study end, treatment group comparisons within obese 
and nonobese subgroups were analyzed using an analysis of 
a covariate model with baseline as a covariate.
Results
Patient disposition and characteristics
Patient disposition was previously described in detail 
(Table 1). Briefly, 662 patients were randomized to phase 3 
double-blind treatment; 233 (35.2%) patients were obese 
at randomization. Sixty-four percent of randomized obese 
patients completed the study, and 67% of nonobese patients 
completed the study. Within the AOM 400 treatment group, a 
numerically larger percentage of obese patients discontinued 
from the study compared with nonobese patients (30.5% vs 
23.5%, respectively; Table 1), although rates of discontinu-
ation due to impending relapse (with or without an adverse 
event) were numerically comparable between obese and 
nonobese patients (Table 1). In both obese and nonobese sub-
populations, baseline and demographic characteristics were 
comparable among treatment groups (Table 2). Obese patients 
were slightly older than nonobese patients. Across treatment 
groups, Asian patients and men were overrepresented in the 
nonobese subpopulations, and more black participants were 
in the obese subpopulations compared with other races.
Efficacy
At week 26, the estimated relapse rate with AOM 400 was 
comparable to that of oral aripiprazole in obese patients 
(6.5% vs 7.9%, respectively; difference, -1.4; 95% CI, -8.93 
to 6.21; P=0.7253) and significantly lower with AOM 400 
versus AOM 50 mg (6.5% vs 30.2%, respectively; differ-
ence, -23.7; 95% CI, -39.60 to -7.80; P=0.0035) in obese 
patients. In nonobese patients, the estimated relapse rate at 
week 26 with AOM 400 was also comparable to that of oral 
aripiprazole (7.4% vs 7.7%, respectively; difference, -0.2; 
95% CI, -6.04 to 5.60; P=0.9412) and significantly lower 
with AOM 400 versus AOM 50 mg (7.4% vs 17.2%, respec-
tively; difference, -9.8; 95% CI, -19.29 to -0.33; P=0.0426). 
At week 38, the observed rate of impending relapse with 
AOM 400 was similar to that observed with oral aripipra-
zole and significantly lower compared with AOM 50 mg 
in obese and nonobese patients (P=0.0012 and P=0.0153, 
respectively; Figure 1).
Table 1 Patient disposition in the randomized phase in obese and nonobese subpopulations
AOM 400 Oral aripiprazole (10–30 mg) AOM 50 mg
Obese Nonobese Obese Nonobese Obese Nonobese
Randomized, n 95 170 95 171 43 88
completed, n (%) 66 (69.5) 130 (76.5) 63 (66.3) 115 (67.3) 19 (44.2) 42 (47.7)
Discontinued, n (%) 29 (30.5) 40 (23.5) 32 (33.7) 56 (32.7) 24 (55.8) 46 (52.3)
aes 5 (5.3) 3 (1.8) 2 (2.1) 5 (2.9) 1 (2.3) 6 (6.8)
impending relapse  
(with ae)
4 (4.2) 9 (5.3) 5 (5.3) 7 (4.1) 6 (14.0) 11 (12.5)
impending relapse  
(without ae)
3 (3.2) 6 (3.5) 3 (3.2) 6 (3.5) 6 (14.0) 6 (6.8)
Patient withdrew consent 8 (8.4) 13 (7.6) 10 (10.5) 19 (11.1) 5 (11.6) 9 (10.2)
Lost to follow-up 2 (2.1) 2 (1.2) 2 (2.1) 8 (4.7) 3 (7.0) 3 (3.4)
Met withdrawal criteria 2 (2.1) 2 (1.2) 3 (3.2) 3 (1.8) 2 (4.7) 3 (3.4)
Withdrawn by investigator 4 (4.2) 4 (2.4) 6 (6.3) 6 (3.5) 1 (2.3) 7 (8.0)
Protocol deviations 1 (1.1) 1 (0.6) 1 (1.1) 2 (1.2) 0 1 (1.1)
Abbreviations: AE, adverse event; AOM 400, aripiprazole once-monthly 400 mg; AOM 50 mg, aripiprazole once-monthly 50 mg.
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safety
The tolerability profile of AOM 400 was similar in obese and 
nonobese patients with schizophrenia. Most TEAEs (10% 
incidence in any treatment group) were comparable between 
obese and nonobese patients within and between treatment 
groups (Figure 2). Rates of injection site pain, reported as 
a TEAE, were higher in obese versus nonobese patients 
who received AOM 400 (11.6% vs 5.3%, respectively); 
however, no patient discontinued because of injection site 
pain. EPS scales showed no differences between obese and 
nonobese patients (data not shown) and were consistent with 
the results from the full study.13 The incidence of potentially 
clinically relevant weight changes, defined a priori as a 7% 
increase or decrease in weight, and mean weight changes 
from baseline to study end are listed by treatment group 
for obese versus nonobese patients in Table 3. At week 38, 
mean weight change was comparable in nonobese patients 
treated with AOM 400 versus oral aripiprazole. However, 
the difference in mean (SD) weight change between non-
obese patients treated with AOM 400 compared with AOM 
50 mg was statistically significant (0.7 [4.2] vs -1.0 [0.4] kg, 
respectively; P0.05; Table 3). In obese patients, mean 
weight change at week 38 was comparable between AOM 
400 and oral aripiprazole and between AOM 400 and AOM 
50 mg (Table 3).
Of note, in patients treated with AOM 400, a numerically 
greater percentage of obese patients had weight loss 7% 
than had weight gain 7% (17.9% vs 10.5%, respectively). 
Within the AOM 400 treatment group, 7.6% of patients went 
from nonobese at baseline to obese at study end, whereas 
17.9% of patients treated with AOM 400 went from obese 
at baseline to nonobese at study end. In the AOM 50 mg and 
oral aripiprazole 10–30-mg treatment groups, percentages 
for patients who went from obese to nonobese and from 
nonobese to obese were similar to those seen in the AOM 
400 treatment arm (Figure 3).
Table 2 Baseline (randomized phase) demographics and characteristics in obese and nonobese subpopulations
AOM 400 Oral aripiprazole (10–30 mg) AOM 50 mg
Obese  
(n=95)
Nonobese 
(n=170)
Obese  
(n=95)
Nonobese 
(n=171)
Obese  
(n=43)
Nonobese 
(n=88)
age, mean (sD), years 43.3 (9.5) 40.8 (10.8) 43.4 (10.7) 40.0 (10.8) 42.8 (8.8) 38.9 (9.8)
Male sex, n (%) 47 (49.5) 113 (66.5) 54 (56.8) 114 (66.7) 19 (44.2) 59 (67.0)
race, n (%)
White 55 (57.9) 105 (61.8) 52 (54.7) 101 (59.1) 24 (55.8) 50 (56.8)
Black 31 (32.6) 25 (14.7) 34 (35.8) 30 (17.5) 18 (41.9) 15 (17.0)
asian 3 (3.2) 26 (15.3) 0 26 (15.2) 1 (2.3) 13 (14.8)
Other 6 (6.3) 14 (8.2) 9 (9.5) 14 (8.2) 0 10 (11.4)
Mean (sD) BMi, kg/m2 36.1 (5.7) 24.9 (2.9) 34.5 (4.8) 25.2 (3.0) 37.5 (7.7) 24.5 (3.2)
Mean weight, kg 102.8 (19.1) 72.6 (12.3) 102.1 (15.9) 73.5 (11.9) 106.7 (24.9) 71.3 (13.1)
Abbreviations: BMI, body mass index; AOM 400, aripiprazole once-monthly 400 mg; AOM 50 mg, aripiprazole once-monthly 50 mg.
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Figure 1 Observed rate of impending relapse in 38-week randomized phase.
Notes: *P=0.0012 vs aOM 400. †P=0.0153 vs aOM 400.
Abbreviations: AOM 400, aripiprazole once-monthly 400 mg; AOM 50 mg, aripiprazole once-monthly 50 mg.
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Across all treatment groups, mean changes from baseline 
were minimal in metabolic parameters, including fasting total 
cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, 
and glucose, although the variation was large within groups 
(Table 3). In obese and nonobese patients treated with 
AOM 400, all mean changes were less than 4% of baseline 
values at week 38, with the exception of triglycerides in 
nonobese patients (mean ± SD increase 11.0±79.4 mg/dL 
from baseline mean of 119.6 mg/dL, n=118). In addition, 
mean ± SD increases in triglycerides (28.4±53.9 mg/dL; 
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Figure 2 Treatment-emergent adverse events (with 10% incidence in any treatment group) in obese and nonobese subpopulations.
Abbreviations: AOM 400, aripiprazole once-monthly 400 mg; AOM 50 mg, aripiprazole once-monthly 50 mg.
Table 3 Weight and metabolic parameters in the randomized treatment phase
AOM 400 Oral aripiprazole (10–30 mg) AOM 50 mg
Obese
n=95
Nonobese
n=170
Obese
n=95
Nonobese
n=171
Obese
n=43
Nonobese
n=88
Patients with weight gain 7%, n (%) 10 (10.5) 32 (18.8) 13 (13.7) 30 (17.5) 3 (7.0) 5 (5.7)
Patients with weight loss 7%, n (%) 17 (17.9) 23 (13.5) 12 (12.6) 15 (8.8) 6 (14.0) 12 (13.6)
Mean (sD) weight change from phase 3  
baseline at week 38,* kg
n=64
-1.1 (5.5)
n=129
0.7 (4.2)
n=60
0.9 (6.0)
n=111
1.1 (4.0)
n=19
-2.9 (11.8)
n=42
-1.0 (4.2)†
Mean (sD) fasting total cholesterol change  
from phase 3 baseline at week 38, mg/dl
n=58
-5.21 (29.93)
n=118
2.00 (24.37)
n=53
-4.47 (23.14)
n=88
-3.55 (29.42)
n=14
5.57 (26.14)
n=34
-8.74 (28.44)
Mean (sD) fasting lDl cholesterol change  
from phase 3 baseline at week 38, mg/dl
n=57
-4.11 (30.55)
n=116
-1.39 (21.33)
n=52
-4.83 (21.30)
n=86
-4.81 (27.23)
n=14
1.93 (19.28)
n=34
-9.76 (27.14)
Mean (sD) fasting hDl cholesterol change  
from phase 3 baseline at week 38, mg/dl
n=58
-0.28 (9.09)
n=118
1.69 (10.17)
n=53
-0.64 (9.02)
n=88
0.18 (9.68)
n=14
-1.93 (7.67)
n=34
2.44 (7.54)
Mean (sD) fasting triglycerides change  
from baseline at week 38, mg/dl
n=58
-4.26 (55.49)
n=118
11.03 (79.40)
n=53
5.66 (73.89)
n=88
5.14 (70.97)
n=14
28.36 (53.93)
n=34
-7.76 (39.46)
Mean (sD) fasting glucose change from 
baseline at week 38, mg/dl
n=58
3.47 (50.22)
n=118
0.76 (15.33)
n=53
0.36 (16.20)
n=85
-1.95 (20.68)
n=14
11.36 (53.09)
n=34
-4.41 (11.29)
Notes: *Weight change 7% was defined a priori as a potentially clinically relevant change. †P0.05 vs aOM 400. No formal statistical comparison was made for metabolic 
parameters other than mean weight change from baseline.
Abbreviation: AOM 400, aripiprazole once-monthly 400 mg; AOM 50 mg, aripiprazole once-monthly 50 mg.
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Figure 3 changes in obesity status from baseline to end of study.
Notes: Dark gray shading denotes patients categorized as nonobese at baseline who shifted to obese at the end of the study. Lighter gray shading denotes patients 
categorized as obese at baseline who shifted to nonobese at the end of the study. Numbers in parentheses indicate the patients within each category who experienced the 
shift in obesity status/total number of patients in the category at baseline.
Abbreviations: AOM 400, aripiprazole once-monthly 400 mg; AOM 50 mg, aripiprazole once-monthly 50 mg.
baseline 115.9 mg/dL) and glucose (11.4±53.1 mg/dL; 
baseline 99.4 mg/dL) were observed at week 38 in obese 
patients who received AOM 50 mg (n=14).
Discussion
The tolerability profile of AOM 400 was comparable 
between obese and nonobese patients with schizophrenia. 
Overall, efficacy outcomes were comparable between 
obese and nonobese patients treated with AOM 400; few 
patients went from nonobese to obese over the course of the 
study, and mean metabolic parameters remained relatively 
stable. The primary efficacy outcome – the noninferiority of 
Kaplan–Meier estimated impending relapse rate at week 26 – 
was met in obese and nonobese subpopulations despite the 
loss of power when dividing the full sample, demonstrat-
ing that AOM 400 was efficacious in both subpopulations. 
Although statistical analyses comparing the primary outcome 
between obese and nonobese patients were not conducted, 
and the study was not specifically powered for this post hoc 
subgroup analysis, estimated impending relapse rates with 
aripiprazole 400 mg at week 26 were low and numerically 
comparable between obese and nonobese patients (6.5% 
and 7.4%, respectively). Similar results were reported in 
a post hoc analysis of risperidone LAI in patients with 
schizophrenia or schizoaffective disorder who were followed 
for 24 months.22 Specifically, efficacy outcomes (ie, time 
to hospitalization, PANSS total score, and the Heinrichs–
Carpenter Quality of Life Scale) were comparable between 
risperidone LAI and oral antipsychotics in subgroups of obese 
(30 kg/m2) and nonobese patients.22 In contrast to other LAI 
antipsychotics that may require dose adjustments for obese 
patients,18 the comparable efficacy and tolerability profile of 
AOM 400 in obese and nonobese patients with schizophrenia 
supports the idea that no weight-based dose adjustments are 
required for AOM therapy.
Because of the association between antipsychotic use 
and metabolic changes,1,3–7 patients should be continu-
ally monitored for weight gain and obesity-related long-
term health problems (eg, cardiovascular disease, type 2 
diabetes)6 while receiving maintenance therapy.1,5 Analyses 
of metabolic changes with olanzapine LAI in patients 
with schizophrenia found that 5.9% of patients who were 
obese at baseline of randomization (BMI 30 kg/m2) had 
a clinically significant (7%) increase in body weight at 
24 weeks (data were not reported separately for nonobese 
patients).23 In a post hoc analysis of metabolic changes with 
paliperidone palmitate treatment in patients with schizo-
phrenia, greater percentages of underweight and normal-
weight patients shifted toward higher BMI categories than 
overweight and obese patients who shifted to lower BMI 
categories.24 From baseline to endpoint of the open-label 
52-week extension study, 15% of normal-weight patients 
(BMI 19–25 kg/m2), 4% of overweight patients (BMI 
25–30 kg/m2), and 6% of obese patients (BMI 30 kg/m2) 
had a 7% increase in body weight. Although weight 
was categorized differently in the study reported here 
(ie, nonobese patients were not separated into normal and 
overweight categories), a similar pattern was observed, in 
that a higher percentage of nonobese patients had 7% 
weight gain compared with obese patients. Notably, a 
greater percentage of patients went from obese to nonobese 
than from nonobese to obese with AOM 400 treatment. 
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The rate of injection site pain, reported as a TEAE, was 
notably lower in nonobese patients compared with obese 
patients (5.3% vs 11.6%, respectively). The lower rate in 
nonobese patients may be secondary to the use of a shorter 
needle in most nonobese patients (21-gauge, 1.5-inch needle 
for patients whose BMI was 28 kg/m2, and 21-gauge, 
2-inch needle for patients whose BMI was 28 kg/m2). 
Among other TEAEs of interest, changes on EPS rating scales 
and rates of akathisia reported as TEAEs were comparable 
between obese and nonobese patients.
Conclusion
In obese and nonobese patients with schizophrenia, the 
tolerability profile of AOM 400 was comparable. AOM 
400 also demonstrated comparable efficacy in obese and 
nonobese patients with schizophrenia. Furthermore, the 
percentage of patients who went from obese to nonobese 
was higher than the percentage of patients who went 
from nonobese to obese. Changes in weight parameters 
from the safety analyses are consistent with the metabolic 
profile of oral aripiprazole.3,4 Nevertheless, weight gain 
is a common side effect of antipsychotic therapy,1 and 
clinical guidelines recommend continuous monitoring of 
metabolic changes and other medication side effects in all 
patients undergoing treatment with atypical antipsychotic 
therapy.1,5
Acknowledgments
This research was supported by Otsuka Pharmaceutical 
Development & Commercialization, Inc., and H Lundbeck 
A/S. Editorial support for the preparation of this manu-
script was provided by Amy Roth Shaberman, PhD, of C4 
MedSolutions, LLC (Yardley, PA, USA), a CHC Group 
company, with funding from Otsuka Pharmaceutical Com-
mercialization & Development, Inc., and H Lundbeck 
A/S.
Disclosure
Marc De Hert has been a consultant for, received grant/
research support and honoraria from, and been on the speak-
ers/advisory boards of Janssen-Cilag, Lundbeck SA, Otsuka, 
and Takeda. Anna Eramo is an employee of Lundbeck LLC. 
Wally Landsberg is an employee of Otsuka Pharmaceutical 
Europe Ltd. Lan-Feng Tsai, Dusan Kostic, and Ross Baker 
are employees of Otsuka Pharmaceutical Development & 
Commercialization, Inc. The authors report no other conflicts 
of interest in this work.
References
 1. Hasan A, Falkai P, Wobrock T, et al; WFSBP Task force on Treat-
ment Guidelines for Schizophrenia. World Federation of Societies of 
Biological Psychiatry (WFSBP) guidelines for biological treatment 
of schizophrenia, part 2: update 2012 on the long-term treatment of 
schizophrenia and management of antipsychotic-induced side effects. 
World J Biol Psychiatry. 2013;14(1):2–44.
 2. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia 
Patient Outcomes Research Team. The Schizophrenia Patient Outcomes 
Research Team (PORT): updated treatment recommendations 2009. 
Schizophr Bull. 2010;36(1):94–103.
 3. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-
generation versus first-generation antipsychotic drugs for schizophrenia: 
a meta-analysis. Lancet. 2009;373(9657):31–41.
 4. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head com-
parisons of metabolic side effects of second generation antipsychotics in 
the treatment of schizophrenia: a systematic review and meta-analysis. 
Schizophr Res. 2010;123(2–3):225–233.
 5. Dixon L, Perkins D, Calmes C. Guideline Watch (September 2009): 
Practice Guideline for the Treatment of Patients with Schizophrenia; 
2009. Available from: http://psychiatryonline.org/pb/assets/raw/
sitewide/practice_guidelines/guidelines/schizophrenia-watch.pdf. 
Accessed April 1, 2015.
 6. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic 
and cardiovascular adverse effects associated with antipsychotic drugs. 
Nat Rev Endocrinol. 2012;8(2):114–126.
 7. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. 
Cardiovascular disease and diabetes in people with severe mental 
illness position statement from the European Psychiatric Association 
(EPA), supported by the European Association for the Study of Diabetes 
(EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 
2009;24(6):412–424.
 8. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with 
severe mental disorders. II. Barriers to care, monitoring and treatment 
guidelines, plus recommendations at the system and individual level. 
World Psychiatry. 2011;10(2):138–151.
 9. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with 
severe mental disorders. I. Prevalence, impact of medications and 
disparities in health care. World Psychiatry. 2011;10(1):52–77.
10. Weber NS, Cowan DN, Millikan AM, Niebuhr DW. Psychiatric and 
general medical conditions comorbid with schizophrenia in the National 
Hospital Discharge Survey. Psychiatr Serv. 2009;60(8):1059–1067.
11. Correll CU, Druss BG, Lombardo I, et al. Findings of a U.S. national 
cardiometabolic screening program among 10,084 psychiatric outpa-
tients. Psychiatr Serv. 2010;61(9):892–898.
12. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, 
is a high-affinity partial agonist at human dopamine D2 receptors. 
J Pharmacol Exp Ther. 2002;302(1):381–389.
13. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-
monthly for treatment of schizophrenia: double-blind, randomised, 
non-inferiority study. Br J Psychiatry. 2014;205(2):135–144.
14. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot 
as maintenance treatment in patients with schizophrenia: a 52-week 
multicenter, randomized, double-blind, placebo-controlled study. 
J Clin Psychiatry. 2012;73(5):617–624.
15. Abilify Maintena® US. aripiprazole. Tokyo, Japan: Otsuka Pharmaceuti-
cal Co., Ltd.; 2013.
16. Abilify Maintena® EU. aripiprazole. Wexham, UK: Otsuka Pharma-
ceutical Europe Ltd.; 2013.
17. Abilify Maintena™ CAN. aripiprazole. Saint-Laurent, QC, Canada: 
Otsuka Canada Pharmaceutical Inc.; 2014.
18. Xeplion®. paliperidone palmitate. Beerse, Belgium: Janssen Pharma-
ceutica N.V.; 2011.
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. 
Acta Psychiatr Scand Suppl. 1970;212:11–19.
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal 
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS, 
and is the official journal of The International Neuropsychiatric 
 Association (INA). The manuscript management system is completely 
online and includes a very quick and fair peer-review system, which 
is all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.
Neuropsychiatric Disease and Treatment 2015:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1306
De hert et al
20. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 
1989;154:672–676.
21. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU 
Assessment Manual for Psychopharmacology. Rockville, MD: US 
Department of Health, Education, and Welfare, Public Health Service, 
Alcohol, Drug Abuse, and Mental Health Administration, National 
Institute of Mental Health, Psychopharmacology Research Branch, 
Division of Extramural Research Programs; 1976:534–537.
22. Leatherman SM, Liang MH, Krystal JH, et al; CSP 555 Investiga-
tors. Differences in treatment effect among clinical subgroups in a 
randomized clinical trial of long-acting injectable risperidone and oral 
antipsychotics in unstable chronic schizophrenia. J Nerv Ment Dis. 
2014;202(1):13–17.
23. McDonnell DP, Kryzhanovskaya LA, Zhao F, Detke HC, Feldman PD. 
Comparison of metabolic changes in patients with schizophrenia 
during randomized treatment with intramuscular olanzapine long-
acting injection versus oral olanzapine. Hum Psychopharmacol. 2011; 
26(6):422–433.
24. Sliwa JK, Fu DJ, Bossie CA, Turkoz I, Alphs L. Body mass index 
and metabolic parameters in patients with schizophrenia during long-
term treatment with paliperidone palmitate. BMC Psychiatry. 2014; 
14(1):52.
